Business
American Diversified Holdings Corporation to Acquire Brazos Biomedical LLC
American Diversified Holdings Corporation to Acquire Brazos Biomedical LLC.
About this update from American Diversified Holdings Corp.
[{"type":"text","content":"DEL MAR, CA / ACCESSWIRE / March 21, 2018 / American Diversified Holdings Corporation (OTC PINK: ADHC) announced today it has reached an agreement to acquire Brazos Biomedical, LLC (BRAZOS), a biomedical device development company based in Houston, TX. Terms of the agreement, which included cash and equity, were not disclosed pending completion of standard due diligence.BRAZOS has a proprietary device (AURACIS™) in pre-clinical development to treat headache pain using transcutaneous electrical nerve stimulation (TENS) technology. AURACIS™ is a new approach to treating migraine using TENS technology to stimulate multiple cranial nerves to alleviate migraine pain. AURACIS™ is placed on the head and with electrodes located at key points delivers mild electrical impulses that mute the pain signals typically associated with migraine headaches. David Foster, Ph.D., J.D. of BRAZOS said, \"AURACIS™ has tremendous potential to alleviate suffering in people who suffer from migraine headaches. Our proprietary technology most closely mimics the most effective treatment for migraine at a fraction of the cost and without the risks of surgical implants.\"Approximately 100 million people in the US experience headaches and more than a third are migraines. Migraine occurs three times more frequently in women than in men and is the third most prevalent and sixth most disabling disease in the world. Most migraines are self-treated with over-the-counter medications that are marginally effective in the majority of cases. Many prescription drugs are also utilized with varying success. The most effective treatment involves the surgical implantation of electrodes which has a reported 80-90% success rate but can cost in excess of $50,000 and is associated with risks common to surgery including infection.ADHC commented, \"The acquisition of BRAZOS is a very significant milestone for the Company. The AURACIS™ device has the potential to transform an unmet medical need for migraine sufferers using a base technology (TENS) that has been used clinically for over twenty years and is generally regarded as safe.\" ADHC continued, \"The acquisition is designed to accelerate product develop and to provide resources for future product innovation and development.\"For more information: www.brazosbio.comAbout American Diversified Holding...